Animal models refers to the animal experimental objects and related materials that can
simulate human body established in medical research. As the second-largest disease in …

The altered activation or overexpression of protein kinases (PKs) is a major subject of
research in oncology and their inhibition using small molecules, protein kinases inhibitors …

Importance Papillary renal cell carcinoma (PRCC) is the most common type of non–clear
cell RCC. Because some cases of PRCC areMET-driven, MET inhibition could be a targeted …

Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited
therapeutic options. PRCC may involve activation of the MET pathway, for example, through …

Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter
of tyrosine kinase inhibitor (TKI) resistance in non–small cell lung cancer (NSCLC) …

MET and its ligand HGF are involved in many biological processes, both physiological and
pathological, making this signaling pathway an attractive therapeutic target in oncology …

The increase in the life expectancy of patients with renal cell carcinoma (RCC) in the last
decade is due to changes that have occurred in the area of preclinical studies …

The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are
becoming the first line of therapy for advanced non-small cell lung cancer (NSCLC) …

Hepatocyte growth factor (HGF) is the ligand for the tyrosine kinase receptor c-Met
(Mesenchymal Epithelial Transition Factor also known as Hepatocyte Growth Factor …

Lack of appropriate models that recapitulate the complexity and heterogeneity of urological
tumours precludes most of the preclinical reagents that target urological tumours from …